Publications by authors named "T Tsunenari"
Tumor markers such as carbohydrate antigen 19-9 (CA19-9) are generally useful in ruling out malignancy of hepatic cysts. The patient was a 72-year-old man who had a ruptured liver cyst in the right liver, which had been noted since he was 67 years old at another hospital. The initial laboratory tests demonstrated elevated CA19-9 (193 784.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to determine if preoperative treatment for pancreatic cancer increases the risk of developing hepatic steatosis (HS) and if HS impacts short-term surgical recovery.
- It involved reviewing medical records of 230 patients who underwent surgery from 2010 to 2023, identifying various risk factors for HS, including factors like female sex, disease stage, and preoperative chemotherapy.
- Results showed that while preoperative HS was linked to several risk factors, it did not influence short-term postoperative complications.
Article Synopsis
- Pancreatic ductal adenocarcinoma (PDAC) has a high recurrence rate, over 70%, and is typically treated with gemcitabine (GEM) chemotherapy, though outcomes are often poor.
- A case study of a 63-year-old woman shows she achieved clinical complete remission for over 7 years after receiving GEM monotherapy, even after developing liver metastases post-surgery.
- Analysis of hENT1 protein levels in tumor tissues suggests that assessing hENT1 expression could help predict the efficacy of GEM treatment in PDAC patients.
Tumor resectability, which is increasingly determined based on preoperative chemotherapy, is critical in determining the best treatment for pancreatic cancers. The present study evaluated the usefulness of serum carbohydrate antigen 19-9 (CA19-9) and the preoperative 8F-fluorodeoxyglucose positron emission tomography/computed tomography standardized uptake value (SUV) percentage change (SUVmax%=[(SUVmax2-SUVmax1)/SUVmax1] ×100, where SUVmax1 and SUVmax2 represent the initial and delayed phases, respectively) as biological factors indicative of tumor resectability. The present study included patients with resectable pancreatic cancer who underwent complete surgical resection, for whom both CA19-9 and SUVmax% were documented using cut-off values of 500 U/ml and 24.
View Article and Find Full Text PDFSmall-cell lung cancer (SCLC) is an aggressive cancer for which immune checkpoint inhibitors (ICI) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives for ICI-resistant tumors, but not all patients with SCLC are responsive. Herein, to integrate CD137 costimulatory function into a T-cell engager format and thereby augment therapeutic efficacy, we generated a CD3/CD137 dual-specific Fab and engineered a DLL3-targeted trispecific antibody (DLL3 trispecific).
View Article and Find Full Text PDF